{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:27:36Z","timestamp":1762475256337,"version":"build-2065373602"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jdcr.2020.12.033","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T16:54:12Z","timestamp":1610470452000},"page":"39-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Nivolumab-associated cutaneous T-cell lymphoma"],"prefix":"10.1016","volume":"9","author":[{"given":"Jennifer A.","family":"Marks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas C.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Crain","family":"Garrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Jo","family":"Lechowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2020.12.033_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14740\/jocmr3750","article-title":"Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study","volume":"11","author":"Bajwa","year":"2019","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.jdcr.2020.12.033_bib2","first-page":"301","article-title":"Management of dermatological adverse events during nivolumab treatment","volume":"13","author":"S\u0142owi\u0144ska","year":"2017","journal-title":"Oncol Clin Pract"},{"key":"10.1016\/j.jdcr.2020.12.033_bib3","first-page":"587","article-title":"NCCN guidelines updates: Management of metastatic kidney cancer","volume":"17","author":"Jonasch","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jdcr.2020.12.033_bib4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2010.08.037","article-title":"S\u00e9zary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)","volume":"64","author":"Olsen","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2020.12.033_bib5","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jaad.2017.12.068","article-title":"Progression of undiagnosed cutaneous lymphoma after anti\u2013tumor necrosis factor-alpha therapy","volume":"78","author":"Martinez-Escala","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"23","key":"10.1016\/j.jdcr.2020.12.033_bib6","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jdcr.2020.12.033_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512621000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512621000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:22:50Z","timestamp":1762474970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512621000175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":7,"alternative-id":["S2352512621000175"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2020.12.033","relation":{},"ISSN":["2352-5126"],"issn-type":[{"type":"print","value":"2352-5126"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nivolumab-associated cutaneous T-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2020.12.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}